Narrow-band imaging and chromoendoscopy for the detecion of colonic dysplasia in inflammatory bowel disease: a prospective and randomized study

Flavio, Feitosa; Carlos, Alexandre de Sousa; Nogueira, José Guilherme; Kishi, Humberto S.; Hashimoto, Cláudio L.; Carrilho, F.J.; Damião, Adérson

doi:10.1097/00054725-201112002-00045

Cited by 11 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The search retrieved 565 citations (Figure ). Twenty‐one trials involving 2889 participants with IBD were eligible for inclusion in the review . We could not extract data from three crossover trials because results at the end of the first phase of the study were not reported.…”

Section: Resultsmentioning

confidence: 99%

“…We could not extract data from three crossover trials because results at the end of the first phase of the study were not reported. Thus, 18 trials involving 2638 participants were included in our analysis . Table S2 shows the study design, interventions and population characteristics in the 21 trials included in the review.…”

Section: Resultsmentioning

confidence: 99%

“…In nine of 21 included trials, a total of 125 participants were excluded after randomisation for insufficient bowel preparation, active colonic inflammation, short disease duration or lack of compliance with the study protocol. Fourteen trials included only participants with ulcerative colitis, six trials enrolled participants with both ulcerative colitis and Crohn's disease, and one trial included participants with ulcerative colitis, Crohn's disease and unclassified colitis …”

Section: Resultsmentioning

confidence: 99%

“…Thus, 18 trials involving 2638 participants were included in our analysis. 29,30,[33][34][35][36][37][38][39][40][42][43][44][45][46][47][48][49] Table S2 shows the study design, interventions and population characteristics in the 21 trials included in the review.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…29 In nine 30,31,34,35,[39][40][41][42]45 of 21 included trials, a total of 125 participants were excluded after randomisation for insufficient bowel preparation, active colonic inflammation, short disease duration or lack of compliance with the study protocol. Fourteen trials [30][31][32]34,37,[39][40][41]43,44,[46][47][48][49] included only participants with ulcerative colitis, six trials 29,33,35,38,42,45 enrolled participants with both ulcerative colitis and Crohn's disease, and one trial included participants with ulcerative colitis, Crohn's disease and unclassified colitis. 36 Eight endoscopic techniques for dysplasia surveillance were evaluated: chromoendoscopy (13 trials), high definition white-light endoscopy (9 trials), narrow band imaging (8 trials), standard definition white-light endoscopy (6 trials), autofluorescence (3 trials), i-SCAN (2 trials), full spectrum high definition white-light endoscopy (Endochoice, Alpharetta, USA) (1 trial) and Fujinon intelligent colour enhancement FICE (Fujifilm, Tokyo, Japan) (1 trial).…”

Section: Study Characteristicsmentioning

confidence: 99%

See 4 more Smart Citations

Systematic review with network meta‐analysis: endoscopic techniques for dysplasia surveillance in inflammatory bowel disease

Iannone

Ruospo²,

Palmer

et al. 2019

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background International guidelines recommend dysplasia surveillance in IBD. Aim To compare endoscopic techniques for dysplasia surveillance Methods We searched MEDLINE, Embase, CENTRAL for randomised trials through May 2019. We estimated odds ratios (ORs) for binary and mean differences (MDs) for continuous outcomes, using frequentist random‐effects network meta‐analysis. We assessed study risk of bias and appraised evidence certainty using GRADE. Results Eighteen trials (2638 participants) were included. Standard definition white‐light endoscopy (OR 0.44, 95% CI 0.26‐0.73; high certainty) and i‐SCAN (OR 0.47, 95% CI 0.25‐0.90; moderate certainty) had lower odds of detecting neoplasia than chromoendoscopy. Fujinon intelligent colour enhancement (FICE), standard definition white‐light endoscopy and i‐SCAN had lower odds for this outcome than full spectrum high definition white‐light endoscopy (ORs 0.02 to 0.15; low certainty). Standard definition white‐light endoscopy had lower odds of detecting nonpolypoid neoplasia than full spectrum high definition white‐light endoscopy, narrow band imaging, chromoendoscopy and high definition white‐light endoscopy (ORs 0.01‐0.14; moderate certainty). Full spectrum high definition white‐light endoscopy ranked as the best technique for both outcomes (moderate certainty). Standard definition white‐light endoscopy had lower odds of detecting neoplasia by target biopsy (OR 0.27, 95% CI 0.08‐0.91) and had shorter procedure time (MD −14.81 minutes, 95% CI −25.03, −4.06) than chromoendoscopy (moderate certainty). Conclusions Chromoendoscopy, high definition white‐light endoscopy, narrow band imaging, autofluorescence, FICE and full spectrum high definition white‐light endoscopy may be comparable for dysplasia surveillance. Standard definition white‐light endoscopy and i‐SCAN probably provide lower yields for neoplasia identification. Full spectrum high definition white‐light endoscopy may represent the first‐line approach.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%